1. Scrip
  2. >>Therapy Areas

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

 
• By Aine Slowey

New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.

Pipeline
Good news for Novo's diabetes pipeline

Novo Nordisk AS’s investigational GLP-1 agonist semaglutide demonstrated a significant reduction in major adverse cardiovascular events in the SUSTAIN-6 cardiovascular outcomes trial, which will strengthen its new drug application for the therapy and supplement future negotiations with pricing regulators.

The full data from the SUSTAIN-6 non-inferiority study were presented on Sept. 16 to rapturous applause at the European Association...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.